Defense and Homeland Security Sector Ideas

[gfp927z]

>>> Cortex Receives Granted US Patent for its Lead AMPAKINE® Molecule Cx1739


http://www.cortexpharm.com/news/index.html



IRVINE, CA (April 26, 2011) — Cortex Pharmaceuticals, Inc. [OTCBB (CORX.OB)] announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent that protects its lead Ampakine® molecule, CX1739. The patent, entitled “Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses,” specifically covers CX1739, Cortex’s third generation Low Impact Ampakine compound that is currently in Phase II clinical development. Along with CX1739, the allowed patent covers approximately 80 additional structures that will have patent protection into 2028.

“We are most appreciative to our Senior Director of Medicinal Chemistry, Leslie Street, Ph.D., and our Director of Chemistry, Rudolf Mueller, Ph.D., who are co-inventors on the allowed patent,” said Dr. Mark A. Varney, Cortex President and CEO.

“This patent will make Cortex’s low impact Ampakine platform more attractive for partnering due to the superiority of these latest Ampakine compounds in potency, safety and patent life over earlier low impact Ampakine compounds. With 17 years of patent life remaining on CX1739 and other compounds in this allowed patent, Cortex looks forward to developing, partnering and commercializing these new Ampakine compounds for the treatment of neurological and cardio-respiratory diseases, as well as psychiatric disorders, such as ADHD, depression and schizophrenia,” said Dr. Varney. “Cortex’s strategy has been to file patents aggressively on new inventions. This patent application has been filed broadly in major markets, and patent prosecution in these other countries continues,” stated Dr Varney.

AMPAKINE compounds have previously demonstrated proof-of-concept in clinical studies in ADHD, and in the prevention of opiate-induced respiratory depression. Earlier this year, Cortex reported results from a Phase IIa sleep lab study with CX1739 in subjects with moderate to severe sleep apnea. The results from this study suggested a potential opportunity for CX1739 in the treatment of central sleep apnea, which is often seen in heart failure patients and chronic opiate users.

Cortex Pharmaceuticals, Inc.
Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for treating psychiatric disorders, neurological diseases and sleep apnea. Cortex is pioneering a class of proprietary pharmaceuticals called Ampakine® compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain’s neurotransmitter system. These imbalances may be improved by using the Ampakine technology. For additional information regarding Cortex, please visit the Company’s website at http://www.cortexpharm.com www.cortexpharm.com

<<<